Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 4 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

All‐cause mortality at 1 year · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus S‐1 changes all‐cause mortality at 1 year compared with S‐1 (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 0.61 [0.33, 1.13]
2 studies · 151 participants
Very low

Serious adverse events · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus S‐1 changes serious adverse events compared with S‐1 (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 1.05 [0.15, 7.1]
1 study · 90 participants
Very low

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Overall response rate · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus S‐1 changes overall response rate compared with S‐1 (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 2.46 [1.27, 4.75]
2 studies · 140 participants
Very low

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus S‐1 changes grade 1 ‐ 4 anaemia compared with S‐1 (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 1.26 [1, 1.59]
2 studies · 151 participants
Very low